Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syros Pharmaceuticals

0.0924
+0.015920.78%
Post-market: 0.0820-0.0104-11.26%19:59 EDT
Volume:81.32M
Turnover:8.90M
Market Cap:2.48M
PE:-0.03
High:0.1275
Open:0.0800
Low:0.0765
Close:0.0765
Loading ...

Syros stock dives 92% on failed Phase 3 study, possible loan default (update)

seekingalpha
·
13 Nov 2024

Syros Pharmaceuticals Inc - -- Select-Mds-1 Did Not Meet Its Primary Endpoint

THOMSON REUTERS
·
13 Nov 2024

Syros Pharmaceuticals Inc - to Discontinue Study and Review Full Data Set

THOMSON REUTERS
·
13 Nov 2024

Syros Announces Topline Data From Select-Mds-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome With Rara Gene Overexpression

THOMSON REUTERS
·
13 Nov 2024

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Business Wire
·
13 Nov 2024

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Simply Wall St.
·
02 Nov 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...

GuruFocus.com
·
01 Nov 2024

Syros Pharmaceuticals Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Nov 2024

Syros Pharmaceuticals Reports Q3 2024 Financial Results

TIPRANKS
·
01 Nov 2024

Syros Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

Syros Pharmaceuticals: Promising Prospects with Strong Cash Position and Advancing Phase 3 Trial in HR-MDS

TIPRANKS
·
31 Oct 2024

Syros Pharmaceuticals: Promising Breakthrough with Tamibarotene in High-Risk MDS

TIPRANKS
·
31 Oct 2024

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

THOMSON REUTERS
·
31 Oct 2024

Syros Pharmaceuticals Q3 Operating Expenses USD 26.182 Million

THOMSON REUTERS
·
31 Oct 2024

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Business Wire
·
31 Oct 2024

Syros Pharmaceuticals Q3 2024 GAAP EPS $(0.16) Beats $(0.72) Estimate. Cash and Equivalents Of $60.4M

Benzinga
·
31 Oct 2024